Future Oncology · 2022 · 23 citations · 25 references
MedicinePharmacologyPharmacotherapyClinical EpidemiologyClinical PharmacologyOncology PharmacotherapyMyeloproliferative NeoplasmsPrognosis AssessmentElectronic Medical RecordsKaplan-meier Confidence IntervalsPatient Medical RecordsUnmet Health NeedUnmet Healthcare Need
Aim: To assess real-world ruxolitinib treatment patterns and outcomes in patients diagnosed with primary or secondary myelofibrosis. Materials & methods: Patient medical records were reviewed in six countries. Results: Eligible patients (n = 469) had a mean age of 63.5 years, and most were male (66.5%) with primary myelofibrosis (78.5%). Median duration of ruxolitinib treatment was 13.1 months; 40% of patients initiated treatment at the recommended dose. The Kaplan–Meier estimate of median survival from ruxolitinib initiation was 44.4 months (95% CI, 38.8–50.2 months). Approximately one quarter (23%) of patients continued ruxolitinib after progression. Conclusion: These results suggest an unmet need for more effective treatments for patients with myelofibrosis who failed ruxolitinib.
25
The National Comprehensive Cancer Network
William T. McGivney · Cancer · 1998 · 16.9K citations
Naseema Gangat, Domenica Caramazza, Rakhee Vaidya et al. · Journal of Clinical Oncology · 2010 · 1K citations · Full text
Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · Journal of Hematology & Oncology · 2017 · 427 citations · Full text
Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi et al. · The Lancet Haematology · 2017 · 330 citations · Full text